Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
| العنوان: | Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma |
|---|---|
| المؤلفون: | Benboubker, Lotfi, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John, Belch, Andrew R., Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, Qiu, Lugui, White, Darrell J., Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason, Jacques, Christian, Ervin-Haynes, Annette, Avet-Loiseau, Hervã©, Hulin, Cyrille, Facon, Thierry, Petrini, Mario |
| المساهمون: | Benboubker, Lotfi, Dimopoulos, Meletios A., Dispenzieri, Angela, Catalano, John, Belch, Andrew R., Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, De La Rubia, Javier, Qiu, Lugui, White, Darrell J., Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason, Jacques, Christian, Ervin-Haynes, Annette, Avet-Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry, Dührsen, Ulrich (Beitragende*r) |
| المصدر: | NEW ENGLAND JOURNAL OF MEDICINE r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Melphalan, Oncology, Adult, Male, medicine.medical_specialty, Medizin, Kaplan-Meier Estimate, Dexamethasone, Disease-Free Survival, Ixazomib, chemistry.chemical_compound, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Middle Aged, Multiple Myeloma, Prednisone, Thalidomide, Medicine (all), Internal medicine, medicine, 80 and over, Multiple myeloma, Lenalidomide, Antineoplastic Combined Chemotherapy Protocol, business.industry, Hazard ratio, General Medicine, medicine.disease, Surgery, Transplantation, chemistry, business, Human, medicine.drug |
| الوصف: | BACKGROUND: The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. METHODS: We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with continuous lenalidomide-dexamethasone versus MPT. RESULTS: The median progression-free survival was 25.5 months with continuous lenalidomide-dexamethasone, 20.7 months with 18 cycles of lenalidomide-dexamethasone, and 21.2 months with MPT (hazard ratio for the risk of progression or death, 0.72 for continuous lenalidomide-dexamethasone vs. MPT and 0.70 for continuous lenalidomide-dexamethasone vs. 18 cycles of lenalidomide-dexamethasone; P |
| وصف الملف: | STAMPA |
| اللغة: | English |
| تدمد: | 0028-4793 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab6a250a554f78e8e5a90914b31416a7Test http://hdl.handle.net/11568/884323Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ab6a250a554f78e8e5a90914b31416a7 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00284793 |
|---|